Enzo Biochem, Inc. v. Applera Corp.
Enzo Biochem, Inc. v. Applera Corp.
Opinion of the Court
ORDER
Defendants-Appellees Applera Corp. and Tropix, Inc. filed a combined petition for panel rehearing and rehearing en banc. The panel requested a response from Plaintiffs-Appellants Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University. The court granted Defendants-Appellees leave to file a reply. The petition for rehearing was considered by the panel that heard the appeal, and thereafter the petition for rehearing en banc, the response to the petition, and reply were referred to the circuit judges who are in regular active service.
Upon consideration thereof,
It Is Ordered That:
(1) The petition of Defendants-Appellees for panel rehearing is denied.
(2) The petition of Defendants-Appellees for rehearing en banc is denied.
(3) The mandate of the court will issue on June 2, 2010.
070rehearing
ON PETITION FOR PANEL ■ REHEARING
dissenting from the denial of the petition for panel rehearing.
I respectfully dissent from the denial of the petition for panel rehearing on the
The corollary derived from this understanding is that if several persons of ordinary skill come up with competing but plausible interpretations of a disputed term — as is typically the case with competing “expert witnesses” in patent infringement litigation — the problem is not one of an inherently ambiguous and potentially indefinite claim term, but rather the problem becomes simply one of picking the “right” interpretation for that term.
The United States Patent and Trademark Office (“PTO”), by contrast, appears to be taking steps to give the statutory requirement real meaning. In 2008, the patent examining corps was given a five-page instruction on “Indefiniteness rejections under 35 U.S.C. § 112, second paragraph.”
This memo was followed later in the year by a rare precedential opinion issued by the Board of Patent Appeals and Interferences (“Board”) in Ex parte Miyazaki,
The Board is clearly right in recognizing that the circumstances are different between pre-issuance and post-issuance application of the definiteness standard with regard to claim terms. At the same time, the PTO and the Board are clearly right in insisting that, if the public notice function of the patent law is to be honored, claim terms must particularly point out and distinctly claim the subject matter of the invention. In my view, this court’s definiteness doctrine could go considerably further in promoting that objective than it currently does, with the not inconsequential benefit of shifting the focus from litigation over claim construction to clarity in claim drafting.
To begin the discussion of how this court could move in that direction, I would grant the petition for panel rehearing. The court now spends a substantial amount of judicial resources trying to make sense of unclear, overbroad, and sometimes incoherent claim terms. It is time for us to move beyond sticking our fingers in the neverending leaks in the dike that supposedly defines and figuratively surrounds a claimed invention. Instead, we might spend some time figuring out how to support the PTO in requiring that the walls surrounding the claimed invention be made of something other than quicksand.
I respectfully dissent from the loss of that opportunity through the panel’s denial of rehearing.
. See, e.g., Datamize, LLC v. Plumtree Software, Inc., 417 F.3d 1342, 1347 (Fed.Cir. 2005) ("Only claims 'not amenable to construction’ or ‘insolubly ambiguous’ are indefinite.” (citing Novo Indus., L.P. v. Micro Molds Corp., 350 F.3d 1348, 1353 (Fed.Cir. 2003); Honeywell Int’l, Inc. v. Int'l Trade Comm'n, 341 F.3d 1332, 1338 (Fed.Cir. 2003); Exxon Research & Eng'g Co. v. United States, 265 F.3d 1371, 1375 (Fed.Cir. 2001))).
. Broad, to the point of inherently ambiguous, claim drafting is not just a matter of poor drafting skills on the part of some lawyers who prosecute patent applications. On the contrary, the art of broad claim drafting is a prized talent — clients are openly urged to use "broad patent protection both offensively to block competitors from the marketplace, and defensively to serve as a bargaining chip against potential patent infringement suits” and to "file patents to cover all aspects of the core technology ... to create a ‘picket fence’ of protection.” David J. Dykeman and Joanna T. Brougher, File, Protect, Update, Defend, Corporate Counsel, May 1, 2010, http://www. law.com/jsp/cc/PubArticleCC.jsp?id= 1202447671049.
. Memorandum from John Love, Deputy Commissioner for Patent Examination Policy, to Technology Center Directors and Patent Examining Corps (Sept. 2, 2008), available at http://www.uspto.gov/web/patents/ memoranda.htm.
. Id. at 1.
. Id. at 2.
. No. 2007-3300, 2008 WL 5105055 (Bd. Pat. App. & Inter., Nov. 19, 2008).
. Id. at *4 (quoting Datamize, 417 F.3d at 1347).
. Id. at *6.
. Id. at *5.
. Id.
Reference
- Full Case Name
- ENZO BIOCHEM, INC., Enzo Life Sciences, Inc., and Yale University, Plaintiffs-Appellants, v. APPLERA CORP. and Tropix, Inc., Defendants-Appellees
- Cited By
- 3 cases
- Status
- Published